Literature DB >> 11007223

The stimulation of antral motility by erythromycin is attenuated by hyperglycemia.

C K Rayner1, Y C Su, S M Doran, K L Jones, C H Malbert, M Horowitz.   

Abstract

OBJECTIVE: Diabetic gastroparesis is usually treated with prokinetic drugs, of which the most potent, when given intravenously during euglycemia, is erythromycin. Recent studies have demonstrated that the gastrokinetic effects of erythromycin are attenuated by hyperglycemia. The aim of this study was to determine whether the effects of erythromycin on antropyloroduodenal motility, including the organization of antral pressure waves, are modified by hyperglycemia.
METHODS: A total of eight healthy male volunteers (median age 24 yr) were studied on 2 days each in randomized order. A manometric assembly, incorporating six antral, two pyloric, and seven duodenal sideholes and a pyloric sleeve sensor, was positioned with the sleeve spanning the pylorus. The blood glucose concentration was stabilized at about 5 mmol/L (euglycemia) or 15 mmol/L (hyperglycemia). After 30 min (T = 0), an intraduodenal lipid infusion (1.5 kcal/min) was commenced and continued until the end of the study. At T = 20 minutes, erythromycin (200 mg) as the lactobionate was infused intravenously over 20 min, followed by 100 mg over the next 40 min.
RESULTS: Intravenous erythromycin increased the amplitude of antral waves during intraduodenal lipid infusion at both blood glucose concentrations (p < 0.01 for euglycemia and p < 0.05 for hyperglycemia). After erythromycin (T = 20 to T = 80), the frequency (p < 0.05) and amplitude (p < 0.01) of antral waves were less during hyperglycemia than euglycemia. Both propagated (p < 0.0005) and nonpropagated (p < 0.01) antral waves were decreased by hyperglycemia, but the suppression of propagated waves was greater (p < 0.05). Erythromycin reduced the frequency (p = 0.09) but increased the amplitude (p < 0.05) of phasic pyloric pressures, and decreased basal pyloric pressure (p < 0.0005). The frequency (p = 0.06) and amplitude (p < 0.05) of phasic pyloric waves during erythromycin infusion were slightly less during hyperglycemia than euglycemia, whereas there was no effect of the blood glucose concentration on basal pyloric pressure. Erythromycin increased the amplitude (p < 0.001) but not the frequency of duodenal waves; the frequency and amplitude of duodenal waves did not differ between the two blood glucose concentrations.
CONCLUSIONS: Hyperglycemia attenuates the stimulation of antral pressures and propagated antral sequences by erythromycin, but not the effects of erythromycin on pyloric or duodenal motility.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11007223     DOI: 10.1111/j.1572-0241.2000.02250.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  11 in total

1.  The effect of erythromycin on gastrointestinal motility in subtotal gastrectomized patients.

Authors:  A-Lan Lee; Choong-Bai Kim
Journal:  J Korean Surg Soc       Date:  2012-02-27

Review 2.  Diabetic gastroparesis: what we have learned and had to unlearn in the past 5 years.

Authors:  Purna Kashyap; Gianrico Farrugia
Journal:  Gut       Date:  2010-09-25       Impact factor: 23.059

Review 3.  Treatment options for patients with severe gastroparesis.

Authors:  Hasse Abrahamsson
Journal:  Gut       Date:  2007-06       Impact factor: 23.059

4.  Noninvasive assessment of the effects of glucagon on the gastric slow wave.

Authors:  L Alan Bradshaw; Jared A Sims; William O Richards
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2007-09-20       Impact factor: 4.052

Review 5.  Gastroparesis--current concepts and considerations.

Authors:  William L Hasler
Journal:  Medscape J Med       Date:  2008-01-23

6.  Diabetic Gastroparesis.

Authors:  Adil E Bharucha; Yogish C Kudva; David O Prichard
Journal:  Endocr Rev       Date:  2019-10-01       Impact factor: 19.871

Review 7.  Upper gastrointestinal function and glycemic control in diabetes mellitus.

Authors:  Reawika Chaikomin; Christopher K Rayner; Karen-L Jones; Michael Horowitz
Journal:  World J Gastroenterol       Date:  2006-09-21       Impact factor: 5.742

8.  The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus.

Authors:  Andrea Shin; Michael Camilleri; Irene Busciglio; Duane Burton; Steven A Smith; Adrian Vella; Michael Ryks; Deborah Rhoten; Alan R Zinsmeister
Journal:  Clin Gastroenterol Hepatol       Date:  2013-04-30       Impact factor: 11.382

9.  Nutritional therapy for the management of diabetic gastroparesis: clinical review.

Authors:  Amena Sadiya
Journal:  Diabetes Metab Syndr Obes       Date:  2012-09-07       Impact factor: 3.168

10.  Glucose absorption and gastric emptying in critical illness.

Authors:  Marianne J Chapman; Robert J L Fraser; Geoffrey Matthews; Antonietta Russo; Max Bellon; Laura K Besanko; Karen L Jones; Ross Butler; Barry Chatterton; Michael Horowitz
Journal:  Crit Care       Date:  2009-08-27       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.